Benzinga | Jan 21, 2022 06:58AM EST

Elanco's Long-Acting Transdermal Buprenorphine for Cats Gains FDA Approval

The FDA has approved Elanco Animal Health Inc (NYSE:ELAN) Zorbium (buprenorphine transdermal solution) to control postoperative pain associated with surgical procedures in cats.

* The approval expands Elanco's pain management offerings for veterinary practices.

* Zorbium provides up to four days of pain control from a single transdermal dose without relying upon owners to administer an opioid after discharge and the need for repeat injections.

* Related: Elanco To Lay Off 20% Senior Management In Organizational Restructure.

* Consistent pain control reassures cat owners and reduces the challenges of administering pain medications at home.

* Zorbium is for topical application in cats only. Following application to the cat, allow a minimum drying time of 30 minutes before direct contact with the application site.

* Related content: Benzinga's Full FDA Calendar.

* Price Action: ELAN shares closed at $26.83 on Thursday.